Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

A Phase III, Multicenter, Rancomized Open-Label Study Evaluating the Efficacy and Safety of MPD3280A (Anti-PD-L1 Antibody)in Combination with Carboplatin + NAB-Paclitaxel for Chemotherapy-Naive Patients with Stage IV NSCLC

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

F. Hoffmann-La Roche Ltd

Start Date

August 1, 2015

End Date

December 30, 2020
 

Administered By

Duke Cancer Institute

Awarded By

F. Hoffmann-La Roche Ltd

Start Date

August 1, 2015

End Date

December 30, 2020